On 15 June 2026, India's Department for Promotion of Industry and Internal Trade (DPIIT) clarified the final documentation and plant-commissioning requirements for the Production Linked Incentive (PLI) Scheme for Pharmaceuticals Phase 2. The window for manufacturers to lock in eligibility for incentive payouts now runs to 30 September 2026.
Businesses that miss milestone deadlines or fail to submit audited certificates of eligible production lose their subsidy entitlement entirely. For mid-sized API and formulation makers, this represents ₹2,600 crore in potential cashflow support over five years—but only if compliance is flawless from now.
Advisory
DPIIT mandated that all Phase 2 applicants must now file audited production certificates quarterly (not annually) and link them to GST returns within 10 days of filing. Non-compliance triggers immediate disqualification from that quarter's incentive payout.
Manufacturers who fail to commission production capacity by 31 August 2026 lose eligibility retroactively to 1 April 2026. No extensions have been granted since the June notification—only a handful of sector-wide appeals remain pending.
From June 2026, PLI payouts are now reconciled against Customs import invoices and DGFT e-auction records. Discrepancies between declared production and import/export filings trigger audits and recovery notices within 60 days.
Businesses must now treat PLI compliance as a live working-capital priority, not a post-fact audit. The June 2026 tightening means internal processes—production tracking, GST filing, auditor coordination—must be integrated and verified monthly. Vinayakam Consultants helps manufacturers build compliant PLI documentation workflows, reconcile production certificates with GST and Customs records, and navigate the auditor-approval process to lock in payouts before the September gate closes. Missing this window costs not just the incentive, but also the working capital it was meant to fund.
Your action checklist
- Obtain auditor appointment letter and define roles for quarterly production-certificate preparation and GST cross-link validation by 5 July 2026.
- Reconcile all production data (from ERP or ledger) against GST returns for Jan–June 2026; flag any discrepancies with Customs e-filings and file a correction (if needed) before 15 July 2026.
- Confirm plant commissioning status with engineering team; if not fully operational, file a Force Majeure or timeline extension request to DPIIT by 20 July 2026 (though likelihood of approval is low as of June 2026).
- Schedule internal audit of PLI records (invoices, BOM, production logs, third-party test certificates) and submit the first quarterly audited certificate to DPIIT by 31 August 2026.
Frequently asked questions
The eligibility window for PLI Pharma Phase 2 closes on 30 September 2026. Manufacturers must meet all documentation and plant-commissioning requirements by this date to secure incentive payouts.
Manufacturers who fail to commission production capacity by 31 August 2026 lose eligibility retroactively to 1 April 2026. No extensions have been granted since the June 2026 notification.
From June 2026, Phase 2 applicants must file audited production certificates quarterly (not annually) and link them to GST returns within 10 days of filing. Non-compliance triggers immediate disqualification from that quarter's incentive payout.